Fekrisoofiabadi Maryam, Fekri Meisam, Moradabadi Alireza, Vahidi Reza, Khaleghi Morteza, Ram Maryam, Dabiri Shahriar
Department of Pathology, Pathology and Stem Cell Research Center, Afzalipour Medical School, Kerman University of Medical Sciences, 22 Bahman Blvd, Kerman, Iran.
Department of Medicine, Montefiore New Rochelle Hospital, Albert Einstein College of Medicine, New York, USA.
BMC Res Notes. 2019 Dec 12;12(1):803. doi: 10.1186/s13104-019-4784-0.
The resistance to antimony-containing glucantime is a major obstacle to successful treatment, especially in endemic areas. Looking the molecular mechanisms involved in this drug resistance will help in choosing the best treatment. The aim of this study was to evaluate the expression of multidrug-resistance 1 (MDR1) and multidrug-resistance protein A (MRPA) genes in acute, chronic non-lupoid, and chronic lupoid forms of dry type cutaneous leishmaniasis (DTCL).
MDR1 gene was over-expressed as 14.4- and 1.56-folds in the chronic lupoid and acute forms compared with the chronic non-lupoid form, respectively. Results comparison showed P < 0.05 between the chronic non-lupoid and acute groups, P < 0.01 between acute and chronic lupoid groups, and P < 0.001 between the chronic non-lupoid and chronic lupoid groups. MRPA gene was over-expressed as 266 and 17.7-fold in the chronic lupoid and chronic non-lupoid forms compared with the acute form, respectively. Statistical analysis showed P < 0.01 between the chronic non-lupoid and chronic lupoid groups, P < 0.05 between acute and chronic non-lupoid groups, and P < 0.001 between the acute and chronic lupoid groups.
对含锑葡糖胺的耐药性是成功治疗的主要障碍，尤其是在流行地区。了解这种耐药性涉及的分子机制将有助于选择最佳治疗方法。本研究的目的是评估多药耐药1（MDR1）和多药耐药蛋白A（MRPA）基因在急性、慢性非类狼疮和慢性类狼疮型干性皮肤利什曼病（DTCL）中的表达。
与慢性非类狼疮型相比，MDR1基因在慢性类狼疮型和急性型中分别过度表达14.4倍和1.56倍。结果比较显示，慢性非类狼疮组与急性组之间P < 0.05，急性组与慢性类狼疮组之间P < 0.01，慢性非类狼疮组与慢性类狼疮组之间P < 0.001。与急性型相比，MRPA基因在慢性类狼疮型和慢性非类狼疮型中分别过度表达266倍和17.7倍。统计分析显示，慢性非类狼疮组与慢性类狼疮组之间P < 0.01，急性组与慢性非类狼疮组之间P < 0.05，急性组与慢性类狼疮组之间P < 0.001。
